Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Cytarabine 11Idarubicin 6fludarabine 5venetoclax 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4posaconazole 3fludarabine phosphate 2Micafungin 2Gemtuzumab 2Filgrastim 2Decitabine 2Daunorubicin 2ruxolitinib 1olutasidenib 1molgramostim 1eltrombopag 1aldesleukin 1aclacinomycins 1Transplantation, Homologous 1Topotecan 1Tobacco Use Cessation Devices 1Thiotepa 1Stem Cell Transplantation 1Safety 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myeloid, Acute × olutasidenib × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡